StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Equities research analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays decreased their price target on Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th.

Cellectis Stock Performance

Shares of CLLS stock opened at $2.00 on Friday. Cellectis has a 12 month low of $1.70 and a 12 month high of $3.77. The company’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $2.13. The firm has a market cap of $111.17 million, a PE ratio of -1.54 and a beta of 3.09. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The business had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period last year, the firm earned ($0.31) earnings per share. Equities research analysts expect that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Long Focus Capital Management LLC raised its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after acquiring an additional 130,000 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Cellectis by 2.9% in the second quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. First Affirmative Financial Network bought a new position in shares of Cellectis in the third quarter valued at about $45,000. Finally, XTX Topco Ltd acquired a new stake in shares of Cellectis during the 2nd quarter worth about $29,000. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.